John W Kozarich Ligand Pharmaceuticals Inc (LGND) insider trading activity

John W Kozarich is Director of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 45,522 shares of LGND, which is worth approximately $7.56 Million. The most recent transaction as insider was on Sep 02, 2025, when has been sold 467 shares (Common Stock) at a price of $162.76 per share, resulting in proceeds of $76,008. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 45.5K

3.94% 3M change

3.99% 12M change

Total Value Held $7.56 Million

JOHN W KOZARICH Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 02 2025	SELL Open market or private sale	$76,008 $162.76 p/Share	467 Reduced 1.02%	45,522 Common Stock
Aug 01 2025	SELL Open market or private sale	$61,587 $131.88 p/Share	467 Reduced 1.01%	45,989 Common Stock
Jul 10 2025	SELL Open market or private sale	$116,750 $125.0 p/Share	934 Reduced 1.97%	46,456 Common Stock
Jun 06 2025	BUY Grant, award, or other acquisition	-	1,209 Added 2.49%	47,390 Common Stock
Jan 17 2025	BUY Exercise of conversion of derivative security	$125,833 $52.3 p/Share	2,406 Added 4.95%	46,181 Common Stock
Jun 14 2024	BUY Grant, award, or other acquisition	-	1,252 Added 2.78%	43,775 Common Stock
Apr 24 2024	BUY Exercise of conversion of derivative security	$113,839 $39.35 p/Share	2,893 Added 6.37%	42,523 Common Stock
Jun 09 2023	BUY Grant, award, or other acquisition	-	1,142 Added 2.8%	39,630 Common Stock
May 16 2023	SELL Open market or private sale	$343,076 $77.2 p/Share	4,444 Reduced 10.35%	38,488 Common Stock
May 08 2023	SELL Open market or private sale	$492,198 $76.81 p/Share	6,408 Reduced 13.18%	42,213 Common Stock
May 08 2023	BUY Exercise of conversion of derivative security	$120,598 $18.82 p/Share	6,408 Added 11.64%	48,621 Common Stock
Jun 10 2022	BUY Grant, award, or other acquisition	-	1,004 Added 2.32%	42,213 Common Stock
Feb 28 2022	SELL Open market or private sale	$93,179 $102.62 p/Share	908 Reduced 2.16%	41,209 Common Stock
Feb 28 2022	BUY Exercise of conversion of derivative security	$91,908 $12.53 p/Share	7,335 Added 14.83%	42,117 Common Stock
Jun 04 2021	BUY Grant, award, or other acquisition	-	630 Added 1.78%	34,782 Common Stock
May 11 2021	SELL Payment of exercise price or tax liability	$50,267 $128.56 p/Share	391 Reduced 1.13%	34,152 Common Stock
May 11 2021	BUY Exercise of conversion of derivative security	$48,930 $10.12 p/Share	4,835 Added 12.28%	34,543 Common Stock
Feb 22 2021	BUY Exercise of conversion of derivative security	$25,300 $10.12 p/Share	2,500 Added 7.76%	29,708 Common Stock

JWK

John W Kozarich

Director

Emeryville, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Value

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

Operation

Value

Type

News

Receive news related to LIGAND PHARMACEUTICALS INC

Track Activities on LGND

Account